Sacituzumab Govitecan (SG; Trodelvy) is a targeted therapy designed for adults with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) who have received hormone therapy and at least two additional treatments for metastatic disease. It is an antibody-drug conjugate that binds to the Trop-2 antigen, delivering a potent chemotherapy directly to cancer cells6. Clinical trials have demonstrated that SG significantly improves progression-free survival and overall survival compared to traditional chemotherapy in this patient population. This therapy offers a new treatment option for patients with HR+/HER2- MBC, who historically have had limited treatment choices and poor survival outcomes. SG's mechanism of action and clinical efficacy make it a valuable addition to the treatment landscape for this challenging form of breast cancer.

Human trophoblast cell-surface antigen-2 (Trop-2) is a membrane glycoprotein involved in cell proliferation and motility, frequently overexpressed in epithelial tumors. Thus, it represents an attractive target for anticancer therapies. Sacituzumab govitecan (SG) is a third-generation antibody-drug conjugate (ADC), consisting of an anti-Trop-2 monoclonal antibody (hRS7), a hydrolysable linker, and a cytotoxin (SN38), which inhibits topoisomerase 1. Specific pharmacological features, such as the high antibody to payload ratio, the ultra-toxic nature of SN38, and the capacity to kill surrounding tumor cells (the bystander effect), make SG a very promising drug for cancer treatment. Moreover, unprecedented results have been observed with SG in patients with heavily pretreated advanced triple-negative breast cancer and hormone-positive/HER2-negative metastatic breast cancer, and the drug has already received approval for these indications in Taiwan. 

The treatment landscape of breast cancer has been greatly changed by the innovative targeting therapies. Antibody-drug conjugates (ADCs) with a representative of trastuzumab deruxtecan (T-DXd) are the most successful ones. The revolutionary next-generation design of ADC transformed to the unprecedented clinical data. T-DXd has been evaluated as treatment of several HER2-expressing cancers, including HER2-positive and HER2-low breast cancer. This is the first HER2-targeted therapy active for HER2-low breast cancer.

In this review we focus on efficacy and toxicity profile of this novel anti-HER2 compound, and provide an update on the most recent results of ongoing clinical trials of T-DXd.

誠摯歡迎各位學員於11月19日(二)18:40登入乳e學院並”加入我的課程+”，收看聆聽講師們分享2024 ESMO治療最新趨勢

2024TIBCS Channel會前訪談特輯(4) 探索乳癌治療的未來

在這場引人入勝的 TIBCS 2024 會前專訪中，由台大楊明翰醫師和李佳真醫師主持，知名專家 Javier Cortés 教授和 Paolo Tarantino 醫師將討論針對 HR+ 晚期乳癌抗藥性的全新策略。此次討論將深入探討ADCs/PI3K/AKT/mTOR pathway,和endocrine therapy的發展趨勢。

這場對談將為 TIBCS 2024 會議上的精彩演講提供一個前瞻預覽，讓大家有機會率先了解乳癌治療中的最新突破與發展方向，精彩內容不容錯過!

 

2024TIBCS Channel會前訪談特輯(3)乳癌中免疫治療與腫瘤浸潤淋巴細胞 (TILs) 的解析

在這場 TIBCS 2024 的獨家訪談中，由台北榮民總醫院乳房外科的陳彥蓁醫師和陳柏方醫師主持，由澳洲知名專家 Sherene Loi 醫師和 新加坡專家Tira Tan 醫師將探討 the potential role of Tumor-Infiltrating Lymphocytes (TILs) in clinical practice and their influence on chemotherapy decisions，特別是在三陰性乳癌中的應用。他們還將討論免疫治療的現狀和未來前景，包括其在新輔助治療後的應用以及與生物標記整合的情況。不要錯過這場關於個人化乳癌治療目前最創新和挑戰的精彩討論。